

Clare Y Slaney

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5739366/publications.pdf>

Version: 2024-02-01

45
papers

2,578
citations

304743

22
h-index

302126

39
g-index

47
all docs

47
docs citations

47
times ranked

4874
citing authors

#	ARTICLE	IF	CITATIONS
1	Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. <i>Nature Medicine</i> , 2012, 18, 1224-1231.	30.7	406
2	Trafficking of T Cells into Tumors. <i>Cancer Research</i> , 2014, 74, 7168-7174.	0.9	313
3	Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy. <i>Journal of Clinical Investigation</i> , 2017, 127, 929-941.	8.2	251
4	Cathepsin B Inhibition Limits Bone Metastasis in Breast Cancer. <i>Cancer Research</i> , 2012, 72, 1199-1209.	0.9	173
5	CARs versus BiTEs: A Comparison between T Cell "Redirection Strategies for Cancer Treatment. <i>Cancer Discovery</i> , 2018, 8, 924-934.	9.4	173
6	Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses. <i>Frontiers in Immunology</i> , 2018, 9, 70.	4.8	120
7	Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic. <i>Molecular Immunology</i> , 2015, 67, 46-57.	2.2	100
8	BMP4 Inhibits Breast Cancer Metastasis by Blocking Myeloid-Derived Suppressor Cell Activity. <i>Cancer Research</i> , 2014, 74, 5091-5102.	0.9	99
9	Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting. <i>Clinical Cancer Research</i> , 2017, 23, 2478-2490.	7.0	95
10	Clinical application of genetically modified T cells in cancer therapy. <i>Clinical and Translational Immunology</i> , 2014, 3, e16.	3.8	94
11	Cellular networks controlling T cell persistence in adoptive cell therapy. <i>Nature Reviews Immunology</i> , 2021, 21, 769-784.	22.7	83
12	Dual PD-1 and CTLA-4 Checkpoint Blockade Promotes Antitumor Immune Responses through CD4 ⁺ Foxp3 ⁺ Cell-Mediated Modulation of CD103 ⁺ Dendritic Cells. <i>Cancer Immunology Research</i> , 2018, 6, 1069-1081.	3.4	67
13	Loss of Host Type-I IFN Signaling Accelerates Metastasis and Impairs NK-cell Antitumor Function in Multiple Models of Breast Cancer. <i>Cancer Immunology Research</i> , 2015, 3, 1207-1217.	3.4	63
14	A Multifunctional Role for Adjuvant Anti-4-1BB Therapy in Augmenting Antitumor Response by Chimeric Antigen Receptor T Cells. <i>Cancer Research</i> , 2017, 77, 1296-1309.	0.9	61
15	Reprogramming the tumor microenvironment to enhance adoptive cellular therapy. <i>Seminars in Immunology</i> , 2016, 28, 64-72.	5.6	52
16	The Emerging Role of Immunosurveillance in Dictating Metastatic Spread in Breast Cancer. <i>Cancer Research</i> , 2013, 73, 5852-5857.	0.9	47
17	Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies. , 2021, 9, e002555.		41
18	Naïve blood monocytes suppress T cell function. A possible mechanism for protection from autoimmunity. <i>Immunology and Cell Biology</i> , 2011, 89, 7-13.	2.3	39

#	ARTICLE	IF	CITATIONS
19	Genetic Redirection of T Cells for the Treatment of Pancreatic Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 56.	2.8	36
20	CD73: A potential biomarker for anti-PD-1 therapy. <i>Oncolimmunology</i> , 2015, 4, e1046675.	4.6	33
21	Glatiramer Acetate Treatment Directly Targets CD11b ⁺ Ly6G ⁺ Monocytes and Enhances the Suppression of Autoreactive T cells in Experimental Autoimmune Encephalomyelitis. <i>Scandinavian Journal of Immunology</i> , 2011, 74, 235-243.	2.7	29
22	Novel combination immunotherapy for pancreatic cancer: potent anti-tumor effects with CD40 agonist and interleukin-15 treatment. <i>Clinical and Translational Immunology</i> , 2020, 9, e1165.	3.8	26
23	Enhancing chimeric antigen receptor T cell immunotherapy against cancer using a nanoemulsion-based vaccine targeting cross-presenting dendritic cells. <i>Clinical and Translational Immunology</i> , 2020, 9, e1157.	3.8	23
24	Tissue-specific tumor microenvironments influence responses to immunotherapies. <i>Clinical and Translational Immunology</i> , 2019, 8, e1094.	3.8	20
25	The role of Type I interferons in immunoregulation of breast cancer metastasis to the bone. <i>Oncolimmunology</i> , 2013, 2, e22339.	4.6	18
26	Enhancing the efficacy of adoptive cellular therapy by targeting tumor-induced immunosuppression. <i>Immunotherapy</i> , 2015, 7, 499-512.	2.0	18
27	A Histone Deacetylase Inhibitor, Panobinostat, Enhances Chimeric Antigen Receptor T-cell Antitumor Effect Against Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 6222-6234.	7.0	17
28	Enterotoxins can support CAR T cells against solid tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 25229-25235.	7.1	16
29	Embryonic Lethality in Homozygous Human Her-2 Transgenic Mice Due to Disruption of the Pds5b Gene. <i>PLoS ONE</i> , 2015, 10, e0136817.	2.5	14
30	Cross-talk between tumors at anatomically distinct sites. <i>FEBS Journal</i> , 2021, 288, 81-90.	4.7	9
31	Challenges and Opportunities for Effective Cancer Immunotherapies. <i>Cancers</i> , 2020, 12, 3164.	3.7	7
32	Enhancing co-stimulation of CAR T cells to improve treatment outcomes in solid cancers. <i>Immunotherapy Advances</i> , 2021, 1, .	3.0	7
33	An ultrastructural investigation of tumors undergoing regression mediated by immunotherapy. <i>Oncotarget</i> , 2017, 8, 115215-115229.	1.8	6
34	A modified superantigen rescues Ly6G ⁺ CD11b ⁺ blood monocyte suppressor function and suppresses antigen-specific inflammation in EAE. <i>Autoimmunity</i> , 2013, 46, 269-278.	2.6	5
35	Primary and metastatic breast tumors cross-talk to influence immunotherapy responses. <i>Oncolimmunology</i> , 2020, 9, 1802979.	4.6	5
36	Enhancing Adoptive Cell Transfer with Combination BRAF-MEK and CDK4/6 Inhibitors in Melanoma. <i>Cancers</i> , 2021, 13, 6342.	3.7	4

#	ARTICLE	IF	CITATIONS
37	Releasing the Brake on Oncolytic Viral Therapy. <i>Clinical Cancer Research</i> , 2015, 21, 5417-5419.	7.0	3
38	Tissue-specific tumour microenvironments are an emerging determinant of immunotherapy responses. <i>Journal of Thoracic Disease</i> , 2020, 12, 4504-4509.	1.4	3
39	Chimeric antigen receptor T cell therapies for thoracic cancers“ challenges and opportunities. <i>Journal of Thoracic Disease</i> , 2020, 12, 4510-4515.	1.4	1
40	Current status, challenges and perspectives: immunotherapy and tumour microenvironment in thoracic cancer. <i>Journal of Thoracic Disease</i> , 2020, 12, 4496-4497.	1.4	0
41	Abstract A104: Eradication of large solid tumors in immunocompetent mice using dual specific CAR T cells and vaccination. , 2016, , .		0
42	Abstract 631: Dual-specific T cells are highly effective in eradicating solid tumors. , 2017, , .		0
43	Abstract PR06: Dual-specific T-cells and an indirect vaccine eradicate large solid tumors. , 2019, , .		0
44	Abstract A048: Targeting the tumor microenvironment to enhance immunotherapy against cancer. , 2019, , .		0
45	45“...Novel combination immunotherapy for boosting and priming immune responses in pancreatic cancer: strong anti-tumour effects with interleukin-15 and CD40 agonist treatment. , 2020, , .		0